As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.
The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.
- Overall Trial
- Study Sites (1)
Evaluation of the course of COVID-19 disease and perceptions among those tested positive – a prospective and retrospective survey based study
Status: Planned (Transit Ethics), pub.
Purpose / Objectives
COVID-19 is a novel disease for which the perceptions in the population, and clinical course to date are still poorly understood and the diagnostic process is still in flux. This study aims to understand the diagnostic process, the course of illness and perceptions about the illness to help medical institutions take relevant measures in the future so that more patients can receive better medical care timely.
- Investigate the course of illness and assess potential risk factors for a complicated course and associated timing
- Understand the rapidity of diagnosis from onset of symptoms
- Investigate perspectives of patients with COVID-19 on their disease and their ability to isolate
All persons tested positive for COVID-19
Persons will be contacted at least once 2 weeks after diagnosis through the Department of Public Health. For a subset of patients, there will be a prospective enrollment starting with the day of diagnosis. Questions addressed include perceptions of disease, mode and timing of diagnosis, symptoms at diagnosis and in follow-up, course of illness, economic consequences of disease.
Documents (password protected)
Responsibilities in overall trial
- Tel. +49 6221 54-0
- Fax +49 6221 54-2618
National Coordinating Investigator
Dr. med. Claudia Denkinger